Frontiers in endocrinology · 2026
Cangfu Daotan decoction treats PCOS-IR through the IL6/JAK2/STAT3/FOXO4 signaling pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ju Wenhan, Zhang Qianwen, Wang Yue, Pan Keying, Li Yuan, Zhao Shuai, Lian Fang
Аннотация
OBJECTIVE: This study aimed to investigate the protective effects and underlying mechanisms of Cangfu Daotan Decoction (CDD) in both vivo and in vitro models of polycystic ovary syndrome with insulin resistance (PCOS-IR).
MATERIALS AND METHODS: Active compounds in CDD were identified using UPLC-HRMS. Network pharmacology and molecular docking analyses were employed to predict key molecular targets. A nd a high-fat diet. In vitro, KGN cells were used to simulate granulosa cell dysfunction associated with PCOS-IR. The regulatory effects of CDD on the IL6/JAK2/STAT3/FOXO4 signaling pathway were further evaluated.
RESULTS: Fifteen active compounds in CDD were preliminarily identified. Ninety-four potential target genes related to the treatment of PCOS-IR were screened. Network pharmacology and molecular docking analyses indicated strong binding affinities between STAT3 and several active compounds of CDD. CDD improved ovarian function and reduced insulin resistance in PCOS model mice. In vitro, CDD also enhanced glucose intake in granulosa cells under PCOS-IR conditions. Both in vivo and in vitro experiments demonstrated that CDD significantly suppressed activation of the IL6/JAK2/STAT3/FOXO4 signaling pathway.
CONCLUSION: CDD may improve ovarian function and insulin resistance in PCOS-IR mice by modulating the IL6/JAK2/STAT3/FOXO4 signaling pathway.
MATERIALS AND METHODS: Active compounds in CDD were identified using UPLC-HRMS. Network pharmacology and molecular docking analyses were employed to predict key molecular targets. A nd a high-fat diet. In vitro, KGN cells were used to simulate granulosa cell dysfunction associated with PCOS-IR. The regulatory effects of CDD on the IL6/JAK2/STAT3/FOXO4 signaling pathway were further evaluated.
RESULTS: Fifteen active compounds in CDD were preliminarily identified. Ninety-four potential target genes related to the treatment of PCOS-IR were screened. Network pharmacology and molecular docking analyses indicated strong binding affinities between STAT3 and several active compounds of CDD. CDD improved ovarian function and reduced insulin resistance in PCOS model mice. In vitro, CDD also enhanced glucose intake in granulosa cells under PCOS-IR conditions. Both in vivo and in vitro experiments demonstrated that CDD significantly suppressed activation of the IL6/JAK2/STAT3/FOXO4 signaling pathway.
CONCLUSION: CDD may improve ovarian function and insulin resistance in PCOS-IR mice by modulating the IL6/JAK2/STAT3/FOXO4 signaling pathway.